There are currently 153 ongoing clinical trials involving Hemophilia
Of the 153 trials,69 trials are in Phase IV
Furthermore, 36 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Hemophilia, a hematological disorder Europe, Asia-Pacific, and North America are some of the prominent regions engaged in Hemophilia-related drug trials.
Hemophilia related clinical trial sponsors
Novo Nordisk AS, Chugai Pharmaceutical Co Ltd, Sanofi, Pfizer Inc, and Bayer AG are some of the notable clinical trial sponsors involved in Hemophilia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Hemophilia
Emicizumab (Hemlibra / RG-6013, ACE-910), and octocog alfa (Advate) are among the key marketed drugs involving Hemophilia.
Emicizumab (Hemlibra / RG-6013, ACE-910) is a humanized monoclonal modified immunoglobulin G4 (IgG4) bi-specific antibody acts as an anti-factor IXa- and anti-factor X or anti-haemophilic agent. It functions via Coagulation Factor IX (Christmas Factor or Plasma Thromboplastin Component or F9 or EC 3.4.21.22) Activator; Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6) Activator mechanism of action. It is formulated as injectable solution for subcutaneous route of administration. Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors, and also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages, newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. Emicizumab was first approved in 2017 and is marketed globally including the US, the UK, Australia, France, and Germany by several pharma giants including F. Hoffmann-La Roche Ltd, JW Pharmaceutical Corp, and Chugai Pharmaceutical Co Ltd.
Antihemophilic factor (recombinant), octocog alfa (Advate) is an antihemophilic factor. It functions via Coagulation Factor VIII (Antihemophilic Factor or AHF or Procoagulant Component or F8) Replacement mechanism of action. It is formulated as injectable lyophilized powder for solution for intravenous route of administration. Advate is indicated for control and prevention of bleeding in adults and children episodes due to hemophilia A, it is also indicated for perioperative management in adults and children with hemophilia A. Advate was first approved in 1994 and is marketed globally including the US, the UK, Australia, France, and Germany by several pharma giants including Takeda Pharmaceutical Co Ltd, and Baxter AG.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer